Epstein’s Associate: Biotech VC Helped Fund Comeback | STAT News

The biotech industry’s complex relationship with figures embroiled in controversy continues to unfold. A recent report from STAT News details how investor Boris Nikolic, whose ties to Jeffrey Epstein surfaced in 2019, has quietly made a comeback in the venture capital world, aided by Alexis Borisy, a prominent biotech venture capitalist. This development raises questions about accountability and the industry’s willingness to distance itself from individuals linked to serious allegations.

Nikolic’s past as chief science and technology advisor to Bill Gates and his co-founding role at Biomatics Capital Partners initially positioned him as a significant player in the biotech investment landscape. However, his connection to Epstein, revealed when Nikolic was named a successor executor in Epstein’s will just days before Epstein’s death, threatened to derail his career. EpsteinWiki details Nikolic’s extensive relationship with Epstein, spanning roughly a decade, despite the financier’s 2008 conviction for soliciting prostitution from an underage girl.

A Decade of Connection

The newly surfaced details, reported by Damian Garde at STAT News, highlight how Borisy, founder of Third Rock Ventures, actively supported Nikolic’s return to prominence. While many in the industry initially distanced themselves from Nikolic following the revelations about his association with Epstein, Borisy reportedly provided opportunities and support that facilitated his re-entry into the biotech VC scene. This support occurred despite the ongoing scrutiny surrounding Epstein’s crimes and the network of individuals connected to him.

The timing of Nikolic’s resurgence is particularly noteworthy. As The Times of Israel reported in 2022, emails released by the House Oversight Committee showed Epstein maintained close ties with influential figures even after his conviction, including interactions with Nikolic at events like the World Economic Forum in Davos as early as 2010. These communications demonstrate a sustained relationship that continued despite Epstein’s criminal history.

The FDA and Leucovorin Approval

In related news, the FDA recently approved leucovorin for a rare disorder without requiring traditional clinical trial data. This decision, while potentially beneficial for patients with this specific condition, raises questions about the standard of evidence typically required for drug approvals. Leucovorin is a medication used to enhance the effectiveness of certain chemotherapy drugs and can too be used to counteract the effects of methotrexate, a drug used to treat cancer and autoimmune diseases. The FDA’s decision to approve it for this rare disorder without trial data suggests a willingness to expedite access to treatment in cases where the necessitate is significant and the potential risks are considered acceptable.

The STAT News Readout newsletter also highlights the complexities of navigating scientific advancement and ethical considerations within the pharmaceutical industry. The approval of leucovorin underscores the challenges of balancing the urgency of providing treatment for rare diseases with the need for rigorous scientific validation.

Novo Nordisk and Weight Loss Drugs

The ongoing demand for Novo Nordisk’s weight loss drugs, Wegovy and Ozempic, continues to dominate headlines. The pharmaceutical giant is struggling to keep up with demand, leading to shortages and concerns about access for patients who genuinely need the medication. These drugs, originally developed for managing type 2 diabetes, have gained popularity for their weight loss effects, creating a surge in demand that has strained supply chains. The situation highlights the challenges of scaling up production to meet unexpected demand for innovative medications.

The broader implications of these developments extend beyond individual cases. The Nikolic situation raises questions about due diligence and ethical considerations within the venture capital community. The FDA’s approval of leucovorin without trial data prompts a discussion about the appropriate balance between expedited access and scientific rigor. And the demand for Novo Nordisk’s weight loss drugs underscores the challenges of ensuring equitable access to innovative medications.

What to Consider Moving Forward

The biotech industry, like any other, is not immune to the influence of individuals with questionable backgrounds. The case of Boris Nikolic serves as a reminder of the importance of thorough vetting and a commitment to ethical principles. While rehabilitation is possible, the industry must carefully consider the potential reputational and ethical risks associated with associating with individuals linked to serious misconduct.

Regarding drug approvals, the FDA’s decision on leucovorin highlights the need for transparency and clear communication about the rationale behind expedited approvals. While expediting access to treatment for rare diseases is commendable, it is crucial to ensure that the decision is based on sound scientific evidence and a thorough assessment of the potential risks and benefits.

Finally, addressing the supply chain challenges for medications like Wegovy and Ozempic requires a multi-faceted approach, including increased production capacity, improved distribution networks, and strategies to prevent hoarding and misuse. Ensuring equitable access to these medications is essential for maximizing their potential benefits and minimizing health disparities.

For ongoing updates on these and other developments in the biotech industry, readers can subscribe to the STAT News Readout newsletter.